{"id":745660,"date":"2018-10-04T05:45:00","date_gmt":"2018-10-04T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/"},"modified":"2025-11-07T01:27:01","modified_gmt":"2025-11-07T06:27:01","slug":"merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/","title":{"rendered":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced new results from the Phase 3 DRIVE-AHEAD clinical trial<br \/>\n      evaluating the efficacy and safety of DELSTRIGO\u2122, a once-daily<br \/>\n      fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC,<br \/>\n      300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg) in<br \/>\n      treatment-na\u00efve adults with HIV-1 infection. The efficacy findings at<br \/>\n      Week 96 in DRIVE-AHEAD were consistent with the findings at Week 48 in<br \/>\n      which DELSTRIGO demonstrated non-inferior efficacy in comparison to a<br \/>\n      fixed-dose combination of efavirenz (EFV, 600 mg), emtricitabine (FTC,<br \/>\n      200 mg) and TDF (300 mg). The pivotal Phase 3, Week 48 data were<br \/>\n      previously presented at the 9<sup>th<\/sup> IAS Conference on HIV Science<br \/>\n      \/ <a href=\"https:\/\/www.ias2017.org\/\" rel=\"nofollow\">IAS<br \/>\n      2017<\/a>.\n    <\/p>\n<p>\n      The new Week 96 findings will be presented today as a late-breaking oral<br \/>\n      presentation at <a href=\"https:\/\/idweek.org\/\" rel=\"nofollow\"><br \/>\n<b>IDWeek<br \/>\n      2018<\/b><br \/>\n<\/a> taking place Oct. 3-7, 2018, in San Francisco.\n    <\/p>\n<p>\n      \u201cLong-term data from this pivotal clinical trial further confirm the<br \/>\n      efficacy and safety of DELSTRIGO in treatment-na\u00efve patients,\u201d said Dr.<br \/>\n      Jean-Michel Molina, Professor of Infectious Diseases, University of<br \/>\n      Paris, and Head of the Infectious Diseases Department at Saint-Louis<br \/>\n      Hospital in Paris, France. \u201cThe data position this fixed-dose<br \/>\n      combination as a new treatment option that can address the needs of<br \/>\n      people living with HIV today.\u201d\n    <\/p>\n<p>\n      <b>Data from DRIVE-AHEAD<\/b>\n    <\/p>\n<p>\n      In DRIVE-AHEAD, 728 participants with no antiretroviral treatment<br \/>\n      history were randomized and received at least one dose of either<br \/>\n      DELSTRIGO or EFV\/FTC\/TDF once daily. In this trial, after 96 weeks of<br \/>\n      treatment, the proportion of participants achieving plasma HIV-1 RNA<br \/>\n      levels less than 50 copies\/mL was 77.5 percent in the group treated with<br \/>\n      DELSTRIGO (doravirine\/3TC\/TDF) and 73.6 percent in the group treated<br \/>\n      with EFV\/FTC\/TDF (treatment difference: 3.8%, 95% confidence interval:<br \/>\n      -2.4, 10.0).\n    <\/p>\n<p>\n      No additional viral drug resistance to doravirine was observed in study<br \/>\n      participants between Week 48 and Week 96, while two study participants<br \/>\n      in the EFV\/FTC\/TDF group developed viral drug resistance to EFV.\n    <\/p>\n<p>\n      At Week 96, the rate of discontinuation of therapy due to adverse events<br \/>\n      was 3.0 percent (11\/364) in the DELSTRIGO group and 7.0 percent (27\/364)<br \/>\n      in the EFV\/FTC\/TDF group. In addition, the three pre-specified<br \/>\n      neuropsychiatric endpoints of dizziness, sleep disorders\/disturbances<br \/>\n      and altered sensorium were significantly less frequent in the DELSTRIGO<br \/>\n      group than in the EFV\/FTC\/TDF group: dizziness (10.2% vs. 38.2%,<br \/>\n      treatment difference: -28%, 95% confidence interval: -33.9, -22.1),<br \/>\n      sleep disorders and disturbances (14.0% vs. 27.5%, treatment difference:<br \/>\n      -13.5%, 95% confidence interval: -19.3, -7.6) and altered sensorium<br \/>\n      (4.9% vs. 8.5%, treatment difference: -3.6%, 95% confidence interval:<br \/>\n      -7.4, 0.1).\n    <\/p>\n<p>\n      The study also reported lower mean changes from baseline in the levels<br \/>\n      of fasting lipids in the DELSTRIGO group compared with the EFV\/FTC\/TDF<br \/>\n      group at Week 96, including LDL-C (-0.6 mg\/dL vs. 10.8 mg\/dL, treatment<br \/>\n      difference: -11.1, 95% confidence interval: -14.8, -7.4) and non-HDL-C<br \/>\n      (-2.1 mg\/dL vs. 15.0 mg\/dL, treatment difference: -17.0, 95% confidence<br \/>\n      interval: -21.1, -13.0).\n    <\/p>\n<p>\n      \u201cAt Merck, we are committed to continued scientific innovation as we<br \/>\n      look for new ways to help improve how HIV is treated. The recent U.S.<br \/>\n      Food and Drug Administration approval of DELSTRIGO represents this<br \/>\n      ongoing commitment,\u201d said Dr. George Hanna, vice president and<br \/>\n      therapeutic area head of infectious diseases, global clinical<br \/>\n      development, Merck Research Laboratories. \u201cWe are pleased to see the<br \/>\n      efficacy results for DELSTRIGO at 96 weeks, which support the initial<br \/>\n      findings seen in the 48 week data.\u201d\n    <\/p>\n<p>\n      On Aug. 30, 2018, DELSTRIGO and PIFELTRO (doravirine) were approved by<br \/>\n      the U.S. Food and Drug Administration (FDA). DELSTRIGO was approved as a<br \/>\n      once-daily fixed-dose combination tablet of doravirine (100 mg), 3TC<br \/>\n      (300 mg) and TDF (300 mg); and PIFELTRO (100 mg), a new non-nucleoside<br \/>\n      reverse transcriptase inhibitor (NNRTI), was approved to be administered<br \/>\n      in combination with other antiretroviral medicines. Both DELSTRIGO and<br \/>\n      PIFELTRO are indicated for the treatment of HIV-1 infection in adult<br \/>\n      patients with no prior antiretroviral treatment experience, and are<br \/>\n      administered orally once daily with or without food. In the U.S.,<br \/>\n      DELSTRIGO contains a boxed warning regarding post-treatment acute<br \/>\n      exacerbation of hepatitis B (HBV) infection. DELSTRIGO<br \/>\n      (doravirine\/3TC\/TDF) does not cure HIV-1 infection or AIDS. On Sept. 20,<br \/>\n      2018, the Committee for Medicinal Products for Human Use (CHMP) of the<br \/>\n      European Medicines Agency (EMA) adopted a positive opinion recommending<br \/>\n      granting of marketing authorization for DELSTRIGO (doravirine\/3TC\/TDF)<br \/>\n      and PIFELTRO (doravirine).\n    <\/p>\n<p>\n      <b>About DRIVE-AHEAD<\/b>\n    <\/p>\n<p>\n      DRIVE-AHEAD is a Phase 3 multicenter, double-blind, randomized clinical<br \/>\n      trial in which 728 participants with no antiretroviral treatment history<br \/>\n      were randomized and received at least one dose of either DELSTRIGO or<br \/>\n      efavirenz\/emtricitabine\/tenofovir disoproxil fumarate (EFV 600 mg\/FTC<br \/>\n      200 mg\/TDF 300 mg) once daily.\u00a0The primary endpoint of the clinical<br \/>\n      trial was the proportion of participants with HIV-1 RNA copies of less<br \/>\n      than 50 copies\/mL at Week 48. The primary safety endpoint was the<br \/>\n      proportion of participants with neuropsychiatric adverse events through<br \/>\n      Week 48 in the following pre-specified categories: dizziness, sleep<br \/>\n      disorders and disturbances and the inability to think clearly or<br \/>\n      concentrate (altered sensorium). The trial consists of a 96-week<br \/>\n      double-blind treatment period (base study) and an open label extension<br \/>\n      after participants complete the base study. Secondary endpoints include<br \/>\n      efficacy at Week 96, an evaluation of the effects of DELSTRIGO and<br \/>\n      EFV\/FTC\/TDF on fasting serum lipids, change from baseline in CD4+ T-cell<br \/>\n      count and evaluation of safety and tolerability. For further information<br \/>\n      regarding DRIVE-AHEAD please visit <a href=\"https:\/\/www.clinicaltrials.gov\/\" rel=\"nofollow\">www.clinicaltrials.gov<\/a><br \/>\n      clinical trial registry number NCT02403674.\n    <\/p>\n<p>\n      <b>Selected Safety Information about DELSTRIGO (doravirine\/3TC\/TDF)<\/b>\n    <\/p>\n<p>\n      <i>Warning: Post treatment Acute Exacerbation of Hepatitis B (HBV)<\/i>\n    <\/p>\n<p>\n      All patients with HIV-1 should be tested for the presence of HBV before<br \/>\n      initiating antiretroviral therapy. Severe acute exacerbations of HBV<br \/>\n      have been reported in patients who are coinfected with HIV-1 and HBV and<br \/>\n      have discontinued products containing 3TC or TDF, which are components<br \/>\n      of DELSTRIGO. Patients coinfected with HIV-1 and HBV who discontinue<br \/>\n      DELSTRIGO should be monitored with both clinical and laboratory<br \/>\n      follow-up for at least several months after stopping DELSTRIGO. If<br \/>\n      appropriate, initiation of anti-HBV therapy may be warranted.\n    <\/p>\n<p>\n      DELSTRIGO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (<i>Hypericum perforatum<\/i>)),<br \/>\n      as significant decreases in doravirine plasma concentrations may occur,<br \/>\n      which may decrease the effectiveness of DELSTRIGO (doravirine\/3TC\/TDF).<br \/>\n      DELSTRIGO is contraindicated in patients with a previous<br \/>\n      hypersensitivity reaction to 3TC.\n    <\/p>\n<p>\n      Renal impairment, including cases of acute renal failure and Fanconi<br \/>\n      syndrome, have been reported with the use of TDF. DELSTRIGO should be<br \/>\n      avoided with concurrent or recent use of a nephrotoxic agent, as cases<br \/>\n      of acute renal failure after initiation of high-dose or multiple NSAIDs<br \/>\n      have been reported in patients with risk factors for renal dysfunction<br \/>\n      who appeared stable on TDF.\n    <\/p>\n<p>\n      Prior to or when initiating DELSTRIGO, and during treatment, assess<br \/>\n      serum creatinine, estimated creatinine clearance, urine glucose and<br \/>\n      urine protein in all patients. In patients with chronic kidney disease,<br \/>\n      also assess serum phosphorus. Discontinue DELSTRIGO in patients who<br \/>\n      develop clinically significant decreases in renal function or evidence<br \/>\n      of Fanconi syndrome. Discontinue DELSTRIGO if estimated creatinine<br \/>\n      clearance declines below 50 mL\/min.\n    <\/p>\n<p>\n      In clinical trials in HIV-1 infected adults, TDF was associated with<br \/>\n      slightly greater decreases in bone mineral density (BMD) and increases<br \/>\n      in biochemical markers of bone metabolism. Serum parathyroid hormone<br \/>\n      levels and 1,25 vitamin D levels were also higher. Cases of osteomalacia<br \/>\n      associated with proximal renal tubulopathy have been reported with the<br \/>\n      use of TDF.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment. Because DELSTRIGO is a complete<br \/>\n      regimen, co-administration with other antiretroviral medications for the<br \/>\n      treatment of HIV-1 infection is not recommended.\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions.\n    <\/p>\n<p>\n      If co-administered with rifabutin, take one tablet of DELSTRIGO once<br \/>\n      daily, followed by one tablet of doravirine (PIFELTRO) approximately 12<br \/>\n      hours after the dose of DELSTRIGO. The most common adverse reactions<br \/>\n      with DELSTRIGO (incidence \u22655%, all intensities) were dizziness (7%),<br \/>\n      nausea (5%) and abnormal dreams (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to DELSTRIGO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      DELSTRIGO due to the potential for HIV-1 transmission. Because DELSTRIGO<br \/>\n      is a fixed-dose combination tablet and the components cannot be altered,<br \/>\n      it is not recommended in patients with estimated creatinine clearance<br \/>\n      less than 50 mL\/min.\n    <\/p>\n<p>\n      <b>Selected Safety Information about PIFELTRO (doravirine)<\/b>\n    <\/p>\n<p>\n      PIFELTRO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (Hypericum<br \/>\n      perforatum)), as significant decreases in PIFELTRO plasma concentrations<br \/>\n      may occur, which may decrease the effectiveness of PIFELTRO. Immune<br \/>\n      reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment. Co-administration of PIFELTRO with<br \/>\n      efavirenz, etravirine or nevirapine is not recommended. If<br \/>\n      co-administered with rifabutin, increase PIFELTRO dosage to one tablet<br \/>\n      twice daily (approximately 12 hours apart).\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions. The safety of PIFELTRO<br \/>\n      is based on two studies, DRIVE-FORWARD and DRIVE-AHEAD. In<br \/>\n      DRIVE-FORWARD, the most common adverse reactions (incidence \u22655%, all<br \/>\n      intensities) were nausea (7%), headache (6%), fatigue (6%), diarrhea<br \/>\n      (5%) and abdominal pain (5%). In DRIVE-AHEAD, the most common adverse<br \/>\n      reactions (incidence \u22655%, all intensities) were dizziness (7%), abnormal<br \/>\n      dreams (5%) and nausea (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to PIFELTRO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      PIFELTRO due to the potential for HIV transmission.\n    <\/p>\n<p>\n      <b>Our Commitment to HIV<\/b>\n    <\/p>\n<p>\n      For more than 30 years, Merck has been committed to scientific research<br \/>\n      and discovery in HIV and we continue to be driven by the conviction that<br \/>\n      more medical advances are still to come. Our focus is on pursuing<br \/>\n      research that addresses unmet medical needs and helps people living with<br \/>\n      HIV and their communities. We remain committed to working hand-in-hand<br \/>\n      with our partners in the global HIV community to address the complex<br \/>\n      challenges to continuing progress.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world&#8217;s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer&#8217;s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for DELSTRIGO (doravirine\/3TC\/TDF)<br \/>\n      at:\u00a0<\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<br \/>\n<b>Patient<br \/>\n      Information for DELSTRIGO (doravirine\/3TC\/TDF) at:\u00a0<\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf<\/b><br \/>\n<\/a><br \/>\n<br \/>\n<b>Please<br \/>\n      see Prescribing Information for PIFELTRO (doravirine) at:\u00a0<\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<br \/>\n<b>Patient<br \/>\n      Information for PIFELTRO (doravirine) at:\u00a0<\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20181004005294r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele<br \/>(267) 305-3558<br \/>or<br \/>Sarra        S. Herzog<br \/>(908) 740-1871<br \/>or<br \/>Investors:<br \/>Teri Loxam<br \/>(908)        740-1986<br \/>or<br \/>Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new results from the Phase 3 DRIVE-AHEAD clinical trial evaluating the efficacy and safety of DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg) in treatment-na\u00efve adults with HIV-1 infection. The efficacy findings at Week 96 in DRIVE-AHEAD were consistent with the findings at Week 48 in which DELSTRIGO demonstrated non-inferior efficacy in comparison to a fixed-dose combination of efavirenz (EFV, 600 mg), emtricitabine (FTC, 200 mg) and TDF (300 mg). The pivotal Phase 3, Week 48 data were previously presented at the 9 th IAS Conference on HIV Science \/ IAS 2017 . The new Week 96 findings will be presented today as a late-breaking oral presentation at IDWeek 2018 taking place Oct. 3-7, 2018, in San Francisco. \u201cLong-term data from this pivotal clinical trial further confirm the efficacy and safety of<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745660","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new results from the Phase 3 DRIVE-AHEAD clinical trial evaluating the efficacy and safety of DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg) in treatment-na\u00efve adults with HIV-1 infection. The efficacy findings at Week 96 in DRIVE-AHEAD were consistent with the findings at Week 48 in which DELSTRIGO demonstrated non-inferior efficacy in comparison to a fixed-dose combination of efavirenz (EFV, 600 mg), emtricitabine (FTC, 200 mg) and TDF (300 mg). The pivotal Phase 3, Week 48 data were previously presented at the 9 th IAS Conference on HIV Science \/ IAS 2017 . The new Week 96 findings will be presented today as a late-breaking oral presentation at IDWeek 2018 taking place Oct. 3-7, 2018, in San Francisco. \u201cLong-term data from this pivotal clinical trial further confirm the efficacy and safety of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\\\/\",\"name\":\"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-10-04T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:27:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new results from the Phase 3 DRIVE-AHEAD clinical trial evaluating the efficacy and safety of DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg) in treatment-na\u00efve adults with HIV-1 infection. The efficacy findings at Week 96 in DRIVE-AHEAD were consistent with the findings at Week 48 in which DELSTRIGO demonstrated non-inferior efficacy in comparison to a fixed-dose combination of efavirenz (EFV, 600 mg), emtricitabine (FTC, 200 mg) and TDF (300 mg). The pivotal Phase 3, Week 48 data were previously presented at the 9 th IAS Conference on HIV Science \/ IAS 2017 . The new Week 96 findings will be presented today as a late-breaking oral presentation at IDWeek 2018 taking place Oct. 3-7, 2018, in San Francisco. \u201cLong-term data from this pivotal clinical trial further confirm the efficacy and safety of","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:01+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/","name":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-10-04T05:45:00+00:00","dateModified":"2025-11-07T06:27:01+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-ahead-study-evaluating-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-for-the-treatment-of-hiv-1-in-treatment-naiv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Na\u00efve Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d64688be-70bf-48cf-9492-f67d6d060b2b","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745660\/revisions"}],"predecessor-version":[{"id":3675009,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745660\/revisions\/3675009"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745660"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}